number of access : ?
number of downloads : ?
ID 115025
Hosogoshi, Hiroki Kansai University|National Center of Neurology and Psychiatry
Iwasa, Kazunori Shujitsu University
Takagishi, Yuriko National Center of Neurology and Psychiatry|Surugadai University
Takebayashi, Yoshitake National Center of Neurology and Psychiatry|Fukushima Medical University
Adachi, Tomonori Shiga University of Medical Science
Oe, Yuki National Center of Neurology and Psychiatry|Kyorin University
Tairako, Yukino National Center of Neurology and Psychiatry|Meiji Gakuin University
Takao, Yumiko Hyogo College of Medicine
Nishie, Hiroyuki Kawasaki Medical School
Kanie, Ayako National Center of Neurology and Psychiatry
Kitahara, Masaki Yokohama City University
Enomoto, Kiyoka Osaka University
Ishii, Hirono Japan Women’s University
Shinmei, Issei National Center of Neurology and Psychiatry|TCBT Counseling Office
Horikoshi, Masaru National Center of Neurology and Psychiatry
Shibata, Masahiko Naragakuen University
Chronic pain
Cognitive behavioral therapy
Multidisciplinary treatment
Quality of life (QOL)
Content Type
Journal Article
Background: Chronic pain is a major health problem, and cognitive behavioral therapy (CBT) is its recommended treatment; however, efforts to develop CBT programs for chronic pain and assess their feasibility are remarkably delayed in Asia. Therefore, we conducted this pilot study to develop a basic individualized CBT for chronic pain (CBT-CP) and assessed its feasibility for use in Japan.
Methods: Our study was an open-labeled before–after trial without a control group conducted cooperatively in five Japanese tertiary care hospitals. Of 24 outpatients, 15, age 20–80, who experienced chronic pain for at least three months were eligible. They underwent an eight-session CBT-CP consisting of relaxation via a breathing method and progressive muscle relaxation, behavioral modification via activity pacing, and cognitive modification via cognitive reconstruction. The EuroQol five-dimensional questionnaire five level (EQ5D-5 L) assessment as the primary outcome and quality of life (QOL), pain severity, disability, catastrophizing, self-efficacy, and depressive symptoms as secondary outcomes were measured using self-administered questionnaires at baseline, post-treatment, and 3-month follow-up. Intention-to-treat analyses were conducted.
Results: Effect size for EQ5D-5 L score was medium from baseline to post-treatment (Hedge’s g = − 0.72, 90% confidence interval = − 1.38 to − 0.05) and up to the 3-month follow-up (g = − 0.60, CI = − 1.22 to 0.02). Effect sizes for mental and role/social QOL, disability, catastrophizing, self-efficacy, and depressive symptoms were medium to large, although those for pain severity and physical QOL were small. The dropout rate was acceptably low at 14%. No severe adverse events occurred.
Conclusion: The findings suggest that CBT-CP warrants a randomized controlled trial in Japan.
Journal Title
BioPsychoSocial Medicine
Springer Nature|BioMed Central
Start Page
Published Date
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
Integrated Arts and Sciences